Positive Press Coverage Somewhat Unlikely to Impact RXi Pharmaceuticals (RXII) Share Price
News headlines about RXi Pharmaceuticals (NASDAQ:RXII) have been trending positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.3680239383947 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- ‘Exciting’ Collaborations Possible for Biotech’s ‘Flexible’ Platform – Streetwise Reports (streetwisereports.com)
- Are These Stocks Are Increasing In Volume?: RXi Pharmaceuticals Corporation (RXII) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- RXi Pharmaceuticals Corporation (NASDAQ:RXII) – Analyzing Analysts’ Recommendations – Nasdaq Journal (press release) (nasdaqjournal.com)
- RXI Pharma (RXII) Reports Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring – StreetInsider.com (streetinsider.com)
- Rxi Pharma: Phase 2 Trial With RXI-109 Meets Primary Effectiveness Objective (rttnews.com)
RXi Pharmaceuticals (RXII) opened at $0.58 on Thursday. RXi Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $1.12.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.